Bionano Targets $30M–$33M Revenue by 2026 with User Growth and Margin Gains
Strategic Shift and Financial Performance
Bionano Genomics (BNGO) recently shared insights from its Q4 2025 earnings call, highlighting a strategic shift in focus and financial progress. The company’s CEO, Robert Holmlin, emphasized the mission to transform pathology workflows through digital, automated, and AI-driven solutions. He cited the hundreds of publications and presentations by users in 2025 as evidence of the company’s progress and value creation.
Holmlin outlined a strategic shift initiated in September 2024, moving away from aggressive installed base expansion to a focus on “profitable growth from high-volume users and selective customer acquisition.” This approach is built on four strategic pillars: supporting and sustaining the existing user base, increasing utilization by routine users, building support for reimbursement and guideline inclusion, and driving profitability through cost control and product quality improvements.
Mark Adamchak, VP of Accounting & Controller, reported that Q4 2025 revenue was $8 million, down 3% from $8.2 million in Q4 2024, but at the high end of the preannounced range of $7.8 million to $8 million. Non-GAAP gross margin for Q4 2025 was 43%, up from 42% a year ago. Additionally, the full-year non-GAAP operating expense reduction reached 47% to $36.6 million.
Holmlin noted that routine use customers make up about 130 or 40% of the user base, collectively operating about 175 systems or 45% of the global installed base. The company also reported a healthy backlog of consumables demand entering 2026, with supply constraints at the end of Q4 expected to resolve in coming quarters.
Outlook for 2026
Bionano is guiding for full-year 2026 revenue of $30 million to $33 million, representing 5% to 16% growth over 2025. For Q1 2026, revenue guidance is $6.5 million to $6.7 million, described as “flat to 3% growth over 2025.” Management expects revenue growth to be driven by new systems and consumables at existing customers, with supply constraints anticipated to ease, supporting increased consumable sales.
A major catalyst for 2026 is the 47% increase in the payment determination for the Category 1 CPT code for OGM in hematologic malignancies, now priced at $1,853.22, up from $1,263.53.
Financial Results
Q4 2025 revenue was $8 million, within the high end of the preannounced range. Full-year 2025 revenue was $28.5 million, down 7% from 2024, but core revenue (excluding $1.7 million in discontinued services) was down 2%.
In Q4, 7,554 nanochannel array Flowcells were sold, down 6% year-over-year; 30,171 Flowcells were sold for the full year, essentially flat year-over-year. Nine OGM systems were installed in Q4, and 32 for the full year, exceeding the original guidance of 15 to 20 installations.
Non-GAAP gross margin for Q4 2025 was 43%, and for the full year was 47%, up from 35% in 2024. Non-GAAP operating expense for Q4 2025 was $9.7 million, and full-year was $36.6 million, marking a significant reduction from $68.9 million in 2024.
Cash, cash equivalents, and available-for-sale securities at year-end stood at $29.6 million, with $10.3 million subject to certain restrictions. The senior secured convertible debt is expected to be fully retired in May 2026.
Consumables and software revenue decreased by 1% to $4.8 million in Q4, attributed to a decline in software revenue offset by growth in consumables.
Q&A Highlights
During the Q&A session, Yi Chen from H.C. Wainwright asked about new OGM system installations for 2026. Holmlin responded that expectations are comparable to what was shipped last year, but the company is not providing specific guidance on the number of installations due to a desire to stay flexible.
Chen also inquired about Flowcell sales expectations for 2026, to which Holmlin stated that consumables volume range would likely track with the revenue growth, which is a wide range. He also highlighted the increase in CPT code pricing as a big driver for 2026 topline growth, expecting it to accelerate adoption and utilization more.
Sentiment Analysis
Analysts maintained a neutral and focused tone, inquiring about system installations, consumables growth, and catalysts, seeking clarity on operational execution. Management’s tone was confident in prepared remarks, with Holmlin emphasizing “confidence and a strong outlook for the full year 2026” and highlighting “all of this progress and support” as a basis for optimism.
Quarter-over-Quarter Comparison
The strategic focus has further shifted from installed base expansion to targeting routine users, with detailed segmentation of customer profiles and revenue contributions. Guidance for 2026 is more precise, with a clear revenue range and explicit mention of catalysts such as CPT code price increases, compared to Q3’s reiteration of prior guidance.
Management highlighted a significant improvement in operating expense reduction and gross margin expansion versus previous quarters. Analysts continue to focus on utilization rates, system installation, and growth catalysts, mirroring the previous quarter’s inquiries but with increased attention to revenue drivers and supply constraints.
Risks and Concerns
Supply chain constraints for consumables impacted Q4 sales, but management expects these issues to resolve in the coming quarters. There is ongoing dependence on routine user adoption and productivity for revenue growth, with management prioritizing this segment for future expansion.
Cash position and debt retirement timelines are highlighted, with the expectation that the senior secured convertible debt will be fully retired in May 2026.
Final Takeaway
Bionano Genomics is advancing its strategy to drive profitable growth by focusing on high-volume routine users and optimizing its customer base, supported by marked improvements in gross margins and operating expenses. The company signals confidence heading into 2026, with revenue guidance of $30 million to $33 million, backed by increased reimbursement rates and a targeted approach to customer acquisition and support. Management highlights the importance of resolving supply constraints and continuing margin expansion as key to achieving its financial and strategic objectives in the coming year.
